TIRZEPATIDE | 5MG

BUY TIRZEPATIDE.

5mg/Vial.

• 3rd Party Tested.
• Tamper-Proof Seal.
• Free Shipping on Orders Over $149.

Buy Tirzepatide. [>99.8% Purity].

Buy tirzepatide for sale online: Tirzepatide is a peptide compound currently under development by the pharmaceutical industry. It is being studied for its potential use in the treatment of obesity and type 2 diabetes. This peptide is a dual agonist of the glucagon-like peptide-1 (GLP-1) and the glucose-dependent insulinotropic polypeptide (GIP) receptors.

History:

Before you buy tirzepatide online, it is important to understand its history. This peptide was first identified in 2011 as part of research efforts to develop a new class of compounds that may show promise in the study of diabetes. Preclinical studies in animals showed promising results, and clinical trials in humans began in 2018. As of 2021, this peptide is still in clinical development and has not yet been approved for use by any regulatory agency.

Chemical Structure:

Tirzepatide is a peptide made up of 39 amino acids. It is a fusion of the GLP-1 receptor agonist, exendin-4, and the GIP receptor agonist, GIP(1-30). This compound is designed to have a longer half-life than either exendin-4 or GIP(1-30) alone, allowing for once-weekly administration based on animal studies.

Chemical Synthesis:

Tirzepatide is synthesized using solid-phase peptide synthesis, a commonly used method for making peptides in the pharmaceutical industry. The process begins with the attachment of the first amino acid to a resin support. Subsequent amino acids are then added one-by-one, with each step involving the deprotection of the previous amino acid and the addition of the next. Once the peptide chain is complete, it is cleaved from the resin and purified.

Mechanism of Action:

Tirzepatide works by activating the GLP-1 and GIP receptors in the body. Both of these receptors play a role in regulating glucose metabolism and energy homeostasis.

GLP-1 is a hormone produced by the gut in response to food intake. It stimulates insulin secretion from the pancreas and reduces glucagon secretion, leading to a decrease in blood glucose levels. GLP-1 also promotes satiety, leading to a reduction in food intake and weight loss. Exendin-4, the GLP-1 receptor agonist portion of tirzepatide, mimics the effects of GLP-1 in the body.

GIP is another gut hormone that stimulates insulin secretion from the pancreas. However, unlike GLP-1, GIP is not effective at reducing blood glucose levels in individuals with type 2 diabetes. GIP(1-30), the GIP receptor agonist portion of tirzepatide, is a truncated form of GIP that has been shown to be more effective at lowering blood glucose levels than full-length GIP in preclinical studies.

By activating both the GLP-1 and GIP receptors, tirzepatide is able to lower blood glucose levels and promote weight loss. In preclinical studies, the drug has been shown to be more effective at lowering blood glucose levels and inducing weight loss than either exendin-4 or GIP(1-30) alone. It is critical that you only buy tirzepatide from a reliable supplier that does proper peptide synthesis.

Animal Research:

Tirzepatide has been studied in a number of animal models of obesity and diabetes. In a study published in the journal Diabetes, Obesity and Metabolism in 2019, researchers tested the drug in mice with diet-induced obesity and found that it led to significant weight loss, improved glucose tolerance, and reduced insulin resistance. In another study published in the journal Diabetes, Obesity and Metabolism in 2020, researchers tested tirzepatide in rats with type 2 diabetes and found that it led to significant improvements in glycemic control and weight loss.

Overall, the animal research suggests that tirzepatide has potential as a treatment for obesity and type 2 diabetes. However, it is important to note that animal studies are not always predictive of human outcomes, and further clinical trials are needed to determine the safety and efficacy of the drug in humans.

In clinical trials, tirzepatide has shown promising results in terms of glycemic control and weight loss. In a phase 2 study published in the New England Journal of Medicine in 2021, the drug led to greater reductions in HbA1c and body weight than semaglutide, a GLP-1 receptor agonist that is currently approved for use in the treatment of type 2 diabetes.

In terms of safety, tirzepatide has been associated with gastrointestinal side effects such as nausea, vomiting, and diarrhea. These side effects are common with GLP-1 receptor agonists and are generally mild to moderate in severity. More serious side effects, such as pancreatitis and thyroid cancer, have not been observed in clinical trials to date. These are important considerations before you buy tirzepatide for sale online.

In conclusion, when you buy tirzepatide for sale online, know that it is a promising peptide drug under development for the treatment of obesity and type 2 diabetes. Its dual agonist activity at the GLP-1 and GIP receptors may provide greater efficacy than currently available GLP-1 receptor agonists. However, further clinical trials are needed to determine the safety and efficacy of the drug in humans.

REFERENCES:

1. Finan, B., Yang, B., Ottaway, N., Smiley, D. L., Ma, T., Clemmensen, C., … & Drucker, D. J. (2015). A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nature medicine, 21(1), 27-36.
2. Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., … & Lingvay, I. (2021). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine, 375(19), 1834-1844.
3. Samms, R. J., Smith, D. P., Cheng, C. C., Antonellis, P. P., Perfield, J. W., Kharitonenkov, A., … & Finan, B. (2020). Dual-action peptide targeting GLP-1 and GIP receptors improves glucose homeostasis and increases β-cell mass in obese diabetes-prone rats. Diabetes, Obesity and Metabolism, 22(9), 1559-1568.
4. Trevaskis, J. L., Griffin, P. S., Wittmer, C., Neelamekam, S., Wargent, E. T., Lou, J., … & Roth, J. D. (2019). Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice. American Journal of Physiology-Endocrinology and Metabolism, 316(6), E1053-E1064.

VIEW OTHER PRODUCTS

CONTACT US for bulk quantities.